Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 25 clinical trials
A Study of PRT2527 in Patients With Advanced Solid Tumors

This is a Phase 1 dose-escalation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

synovial sarcoma
triple negative breast cancer
  • 05 Jul, 2022
  • 6 locations
HMBD-001 in Advanced HER3 Positive Solid Tumours

This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in patients with advanced HER3 positive solid tumours. The main aims are to find out the maximum dose of HMBD-001 that can be given safely to patients alone and in combination with other anti-cancer agents, more about …

lung cancer
cancer of the ovary
monoclonal antibodies
bladder tumor
  • 20 Dec, 2021
  • 2 locations
Study of Lorlatinib in ROS1 Rearranged NSCLC

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.

proto-oncogene tyrosine-protein kinase ros
cancer chemotherapy
measurable disease
kidney function test
  • 27 Apr, 2022
  • 1 location
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells by blocking some of the enzymes …

tumor cells
monoclonal antibodies
  • 23 Oct, 2022
  • 190 locations
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or without gene alterations in the Hippo pathway for whom …

formalin-fixed paraffin-embedded
  • 20 Jun, 2022
  • 4 locations
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib (ON-TRK)

the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This

  • 23 Oct, 2022
  • 54 locations
Impact of Donor Clonal Haematopoiesis of Indeterminate Potential (CHIP) on Recipient Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (Allo-HSCT)

Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed …

  • 25 Oct, 2022
  • 1 location
Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

The objective of this registry is to analyze treatment reality and outcome of patients with locally advanced or metastatic solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3

  • 22 Dec, 2021
  • 10 locations
Special Drug Use Investigation for Larotrectinib

Researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called TRK fusion cancer. In people with TRK fusion cancer, a gene called neurotrophic TRK, (NTRK) joins or "fuses" with another gene. This creates a protein known as a …

  • 14 Oct, 2022
  • 1 location
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every …

primary cancer
  • 12 Aug, 2021
  • 41 locations